|
1
|
Agostinelli C, Piccaluga PP, Went P, et
al: Peripheral T cell lymphoma, not otherwise specified: the stuff
of genes, dreams and therapies. J Clin Pathol. 61:1160–1167.
2008.
|
|
2
|
Piccaluga PP, Agostinelli C, Gazzola A, et
al: Prognostic markers in peripheral T-cell lymphoma. Curr Hematol
Malig Rep. 5:222–228. 2010.
|
|
3
|
Foss FM, Zinzani PL, Vose JM, et al:
Peripheral T-cell lymphoma. Blood. 117:6756–6767. 2011.
|
|
4
|
Savage KJ: Therapies for peripheral T-cell
lymphomas. Hematology Am Soc Hematol Educ Program. 2011:515–524.
2011.
|
|
5
|
Zinzani PL, Venturini F, Stefoni V, et al:
Gemcitabine as single agent in pretreated T-cell lymphoma patients:
evaluation of the long-term outcome. Ann Oncol. 21:860–863.
2010.
|
|
6
|
Pulini S, Rupoli S, Goteri G, et al:
Pegylated liposomal doxorubicin in the treatment of primary
cutaneous T-cell lymphomas. Haematologica. 92:686–689. 2007.
|
|
7
|
Winer JB: Guillain-Barré Syndrome. Mol
Pathol. 54:381–385. 2001.
|
|
8
|
Hughes RA and Cornblath DR: Guillain-Barré
syndrome. Lancet. 366:1653–1666. 2005.
|
|
9
|
Yuki N and Hartung HP: Guillain-Barré
syndrome. New Engl J Med. 366:2294–2304. 2012.
|
|
10
|
Hughes RA, Swan AV, Raphaël JC, et al:
Immunotherapy for Guillain-Barré syndrome: a systematic review.
Brain. 130:2245–2257. 2007.
|
|
11
|
Rupniewska ZM: Role of the Ann Arbor
classification in the staging of non-Hodgkin’s lymphomas. Pol Arch
Med Wewn. 61:317–321. 1979.
|
|
12
|
Ciesla N, Dinglas V, Fan E, et al: Manual
muscle testing: a method of measuring extremity muscle strength
applied to critically ill patients. J Vis Exp. 50:26322011.
|
|
13
|
Lisak RP, Mitchell M, Zweiman B, et al:
Guillain-Barré syndrome and Hodgkin’s disease: Three cases with
immunological studies. Ann Neurol. 1:72–78. 1977.
|
|
14
|
Julien J, Vital C, Aupy G, et al:
Guillain-Barré syndrome and Hodgkin’s disease: Ultrastructural
study of a peripheral nerve. J Neurol Sci. 45:23–27. 1980.
|
|
15
|
Fujisaki G, Kami M, Murashige N, et al:
Guillain-Barré syndrome associated with rapid immune reconstitution
following allogeneic hematopoietic stem cell transplantation. Bone
Marrow Transplant. 37:617–619. 2006.
|
|
16
|
Hernández-Boluda JC, Lis MJ, Goterris R,
et al: Guillain-Barré syndrome associated with cytomegalovirus
infection after allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis. 7:93–96. 2005.
|
|
17
|
Rodriguez V, Kuehnle I, Heslop HE, et al:
Guillain-Barré syndrome after allogeneic hematopoietic stem cell
transplantation. Bone Marrow Transplant. 29:5152002.
|
|
18
|
Sasannejad P, Azarpazhooh MR, Rahimi H, et
al: Guillain-Barré-like Syndrome, as a Rare Presentation of Adult
T-cell Leukemia-Lymphoma (ATLL): A Case Report. Iran Red Crescent
Med J. 14:4972012.
|
|
19
|
Re D, Schwenk A, Hegener P, et al:
Guillain-Barré syndrome in a patient with non-Hodgkin’s lymphoma.
Ann Oncol. 11:217–220. 2000.
|
|
20
|
Polo-Romero FJ, Sánchez-Beteta P,
Perona-Buendía P and Pérez-García AM: Guillain-Barré syndrome as
first presentation of non-Hodgkin lymphoma. Neurologia. 27:511–513.
2012.
|
|
21
|
Machida H, Shinohara T, Hatakeyama N, et
al: CD5-positive diffuse large B cell lymphoma infiltrating the
central nervous system presenting Guillain-Barré-like syndrome
after chemotherapy. J Clin Exp Hematopathol. 52:199–204. 2012.
|
|
22
|
Kirkwood JM, Butterfield LH, Tarhini AA,
et al: Immunotherapy of cancer in 2012. CA Cancer J Clin.
62:309–335. 2012.
|
|
23
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
|
|
24
|
Stevens PL and Reddy NM: Immune
surveillance and lymphoid malignancy in immunocompromised host. Am
J Blood Res. 3:912013.
|
|
25
|
de la Cruz-Merino L, Lejeune M, Nogales
Fernández E, et al: Role of immune escape mechanisms in Hodgkin’s
lymphoma development and progression: a whole new world with
therapeutic implications. Clin Dev Immunol. 2012:7563532012.
|
|
26
|
Steiner I, Rosenberg G and Wirguin I:
Transient immunosuppression: a bridge between infection and the
atypical autoimmunity of Guillain-Barré syndrome? Clin Exp Immunol.
162:32–40. 2010.
|
|
27
|
Tiwari M: From tumor immunology to cancer
immunotherapy: miles to go. J Cancer Res Ther. 6:427–31. 2010.
|
|
28
|
Couzin-Frankel J: Immune therapy steps up
the attack. Science. 330:440–443. 2010.
|
